The short answer is no, not usually. A basic 5-panel or 10-panel drug test, the kind most employers, staffing agencies, and clinics have relied on for decades, was not built to catch fentanyl. If fentanyl detection matters for your program, whether that is a safety-sensitive workplace, a treatment setting, or a corrections or probation program, you need a panel that lists fentanyl, often abbreviated FYL, as its own named analyte. Here is what actually gets tested on a standard panel, what changed recently at the federal level, and why fentanyl and its analogs require a different kind of test than the opiates most cups already screen for.
What counts as a "standard" drug test
The federal workplace drug testing program built by the Substance Abuse and Mental Health Services Administration (SAMHSA) has long anchored what most commercial 5-panel and 10-panel cups screen for: marijuana metabolites (THC), cocaine, amphetamines, opiates, and phencyclidine (PCP). The National Institute on Drug Abuse notes that opioids are actually a broad drug class covering heroin, fentanyl, and prescription pain relievers like oxycodone, hydrocodone, codeine, and morphine, and that "there is currently no drug test that tests for all opioids." A standard opiate immunoassay is built and calibrated around morphine and codeine, which is why it reliably catches heroin (through its unique metabolite, 6-AM) and prescription opiates, but not necessarily fentanyl, a fully synthetic opioid with a different molecular structure than the opiate class it gets lumped in with in everyday conversation. See NIDA's drug testing overview for the full breakdown of opioid subclasses and why they test differently.
The federal panel added fentanyl. Most workplace testing has not caught up
SAMHSA's Mandatory Guidelines for Federal Workplace Drug Testing Programs did add fentanyl as a named analyte on the Authorized Drug Testing Panel, but not until relatively recently. SAMHSA's own program FAQ states plainly: "Testing for the synthetic opioid, fentanyl, is included in the Authorized Drug Testing Panel with an effective date of July 7, 2025." That change came out of a final rule published in the Federal Register in January 2025. You can read SAMHSA's drug-free workplace FAQ and the underlying final rule adding fentanyl to the federal panel directly.
That rule covers federal agency testing. It does not automatically extend to DOT-regulated safety-sensitive testing under 49 CFR Part 40, the rules that govern truck drivers, pilots, rail crews, and other transportation workers. As of this writing, DOT has only proposed, not finalized, adding fentanyl and its metabolite norfentanyl to Part 40 panels. That proposed rule was published in September 2025 and is not yet in effect. See the DOT proposed rule on adding fentanyl to transportation testing. In practical terms, that means a DOT-regulated collection today still cannot lawfully screen for fentanyl under Part 40, and a great many private employers, staffing firms, and clinics that never adopted the federal panel are still running the older base panel that never included it either. If fentanyl matters to your program, you cannot assume your current cup or card already covers it. Check the analyte list.
Why a standard opiate strip misses fentanyl
The chemistry is the reason a base opiate test is not a fentanyl test. Immunoassay opiate screens use antibodies tuned to recognize morphine and codeine and their close relatives. Fentanyl is a synthetic opioid built on a different chemical backbone, so it does not reliably cross-react with a standard opiate antibody at the concentrations typically found in urine. That is exactly why fentanyl needs its own dedicated analyte on the strip or cup rather than riding along under the general "OPI" result. A panel that specifically lists FYL, such as a 12-panel drug test built to include fentanyl alongside the standard base drugs, closes that gap in a single collection instead of requiring a second visit or a send-out.
Fentanyl screening cutoffs and detection windows
Because fentanyl is active in the body at far smaller concentrations than the opiates a standard panel targets, FDA-cleared fentanyl immunoassays are built with much lower screening cutoffs than a typical opiate test. A SAMHSA-hosted comparison of FDA-cleared fentanyl assays lists screening cutoffs clustered at 1 ng/mL and 2 ng/mL, an order of magnitude (or more) below the cutoffs used for standard morphine-class opiate screens. See the SAMHSA fentanyl immunoassay comparison for the full assay list. A test that is not calibrated to that low a threshold, or that was never designed to look for fentanyl at all, will not flag it.
Detection windows matter just as much as cutoffs. A 2025 study published through the National Institutes of Health estimated a predicted urinary detection window for fentanyl of roughly 13.0 to 130.9 hours, and a longer window of roughly 64.8 to 255.9 hours for its metabolite, norfentanyl, based on a clinical sample of people with opioid use disorder. Individual results vary with dose, frequency of use, hydration, and metabolism, so these are estimates rather than guarantees, but they illustrate why timing a collection matters. See the PubMed study on fentanyl and norfentanyl urinary detection windows.
| Analyte | Typical screening cutoff | Approximate urine detection window |
|---|---|---|
| Fentanyl (parent drug) | 1 to 2 ng/mL on FDA-cleared immunoassays | Roughly 13 to 131 hours (about half a day to five and a half days) |
| Norfentanyl (metabolite) | Screened alongside fentanyl on most FYL-inclusive panels | Roughly 65 to 256 hours (about three to eleven days) |
Fentanyl analogs add another layer of difficulty
Fentanyl itself is a Schedule II controlled substance under federal law, listed directly in the DEA's own schedule of controlled substances. The illicit drug supply, however, does not stay confined to fentanyl alone. Clandestine chemists have produced a range of fentanyl-related analogs, close chemical cousins with slightly altered structures. In late 2023 the DEA finalized a rule permanently placing nine specific fentanyl-related substances into Schedule I, treating them as having no accepted medical use, a status separate from fentanyl itself. Read the DEA final rule scheduling fentanyl-related substances.
That matters for testing because an immunoassay calibrated tightly to fentanyl and norfentanyl is not guaranteed to flag every analog with the same sensitivity. A structurally distant analog can, in some cases, produce a weaker signal or slip past a screen entirely. This is one of the reasons a non-negative fentanyl screen, or any result that seems inconsistent with the clinical picture, should go to laboratory confirmation with GC-MS or LC-MS rather than being treated as final on the strip alone. It is also why programs monitoring high-risk populations increasingly pair fentanyl screening with testing for other substances showing up in the same illicit supply, such as xylazine. Our guide to xylazine and tranq detection covers a closely related blind spot that shows up alongside illicit fentanyl.
What this means for building a testing program
If your standard collection is a base 5-panel or a 10-panel cup that does not name fentanyl as an analyte, add it deliberately rather than assuming it is already covered. Compare your current panel against a standard 10-panel drug screen breakdown to see exactly what is and is not included, then decide whether an FYL-inclusive cup, a standalone fentanyl dip strip added to your existing process, or a broader expanded panel fits your population and risk profile. Clinics monitoring medication-assisted treatment, corrections and probation programs, staffing agencies placing workers in high-risk environments, and any employer outside DOT's current Part 40 rules who wants fentanyl coverage should treat this as a deliberate panel decision, not an assumption.
Frequently asked questions
Does a standard 5-panel drug test detect fentanyl?
Generally, no. The traditional 5-panel screens for marijuana, cocaine, amphetamines, opiates, and PCP. Fentanyl is chemically distinct from the opiates that panel's antibody targets, so it is not reliably caught unless the panel specifically lists fentanyl, or FYL, as its own analyte.
Does DOT drug testing include fentanyl?
Not yet as a finalized requirement. DOT proposed adding fentanyl and norfentanyl to its 49 CFR Part 40 testing panels in a rule published in September 2025, but that rule had not taken effect as of this writing. DOT-regulated safety-sensitive testing continues to run on the existing panel until a final rule is published.
How long does fentanyl stay in urine?
A 2025 NIH-published study estimated a urinary detection window of roughly 13 to 131 hours for fentanyl itself, with its metabolite, norfentanyl, detectable longer, roughly 65 to 256 hours. Actual detection time depends on dose, frequency of use, and individual metabolism.
Why do fentanyl test cutoffs look different from other opiate cutoffs?
Fentanyl is active at far lower concentrations than morphine-class opiates, so FDA-cleared fentanyl immunoassays are built with much lower screening cutoffs, commonly 1 to 2 ng/mL, compared with the cutoffs used on a standard opiate panel. A test not built or calibrated for that threshold will not reliably flag fentanyl.
Can a fentanyl screen miss an illicit fentanyl analog?
It can. Analogs are chemically similar to fentanyl but not identical, and an immunoassay calibrated to fentanyl and norfentanyl is not guaranteed to cross-react the same way with every analog. Any non-negative or clinically questionable result should go to laboratory confirmation testing rather than being read from the screen alone.
Related reading
This article is general information, not legal or medical advice. Panel selection, cutoff levels, and regulatory requirements for fentanyl testing vary by jurisdiction and program type, and should be confirmed with a compliance professional or certified laboratory before you build or change a testing protocol.
